| 前收市價 | 27.10 |
| 開市 | 27.10 |
| 買盤 | 18.35 |
| 賣出價 | 21.45 |
| 拍板 | 292.50 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 27.10 - 27.10 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
BenzingaAmgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
ZacksThe Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Motley FoolIs Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly's biggest growth drivers today are its weight loss drugs.
